Tower Research Capital (TRC)’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-55
| Closed | – | – | 5339 |
|
|
2020
Q2 | $0 | Sell |
55
-590
| -91% | -$1.12K | ﹤0.01% | 5160 |
|
|
2020
Q1 | $1K | Buy |
+645
| New | +$1.32K | ﹤0.01% | 2931 |
|
|
2019
Q4 | – | Sell |
-2,672
| Closed | -$14K | – | 4805 |
|
|
2019
Q3 | $14K | Buy |
2,672
+1,616
| +153% | +$10.8K | ﹤0.01% | 2748 |
|
|
2019
Q2 | $10K | Buy |
+1,056
| New | +$19.4K | ﹤0.01% | 2590 |
|
|
2019
Q1 | – | Sell |
-467
| Closed | -$10K | – | 4606 |
|
|
2018
Q4 | $10K | Sell |
467
-198
| -30% | -$7.74K | ﹤0.01% | 2498 |
|
|
2018
Q3 | $37K | Buy |
+665
| New | +$42.5K | ﹤0.01% | 1956 |
|
|
2017
Q4 | – | Sell |
-172
| Closed | -$23K | – | 4281 |
|
|
2017
Q3 | $23K | Buy |
+172
| New | +$23K | ﹤0.01% | 2661 |
|
|
2016
Q1 | – | Sell |
-12
| Closed | -$2K | – | 5288 |
|
|
2015
Q4 | $2K | Sell |
12
-409
| -97% | -$81.6K | ﹤0.01% | 3882 |
|
|
2015
Q3 | $63K | Buy |
421
+411
| +4,110% | +$302K | 0.01% | 865 |
|
|
2015
Q2 | $10K | Sell |
10
-59
| -86% | -$48.2K | ﹤0.01% | 2736 |
|
|
2015
Q1 | $51K | Buy |
69
+66
| +2,200% | +$49.6K | 0.01% | 1460 |
|
|
2014
Q4 | $2K | Buy |
+3
| New | +$1.61K | ﹤0.01% | 3442 |
|
|
2014
Q2 | – | Sell |
-22
| Closed | -$5K | – | 4876 |
|
|
2014
Q1 | $5K | Sell |
22
-12
| -35% | -$3.34K | ﹤0.01% | 3327 |
|
|
2013
Q4 | $9K | Sell |
34
-224
| -87% | -$53.4K | ﹤0.01% | 3124 |
|
|
2013
Q3 | $59K | Sell |
258
-419
| -62% | -$73.2K | 0.01% | 1770 |
|
|
2013
Q2 | $96K | Buy |
+677
| New | +$107K | 0.01% | 525 |
|
Tower Research Capital (TRC)'s TTPH Position: Q3 2020 in Review
Tower Research Capital (TRC) sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2020, closing a stake of 55 shares.
Tower Research Capital (TRC) first reported a position in TTPH in Q2 2013 and held it in 16 quarters. The position peaked at $96K in Q2 2013. 1 fund tracked by Wall St. Rank holds TTPH as of Q3 2020.
- Tower Research Capital (TRC) reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Tower Research Capital (TRC) sold 55 Tetraphase Pharmaceuticals, Inc. shares in Q3 2020.
- Tower Research Capital (TRC) first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2013 and held it in 16 quarters.
- Tower Research Capital (TRC)'s Tetraphase Pharmaceuticals, Inc. position peaked at $96K in Q2 2013.
- 1 fund tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2020.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2020, filed 16 Nov 2020.